Skip to main content
Industry News
Drugmakers race to develop COVID-19 treatments

AbCellera Biologics and Eli Lilly and Co. said they will work together to develop antibody products that can be used to prevent and treat COVID-19, the disease caused by the novel coronavirus, and their goal is to start testing in patients within the next four months. Biogen also agreed to collaborate with Vir Biotechnology to advance the development of Vir's human monoclonal antibodies as potential therapies for COVID-19.

Full Story: